Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

FDA Approves Ozempic for Treatment of T2D

Novo Nordisk news release; 2017 Dec 5

The FDA has approved Ozempic (semaglutide) injection for the treatment of adults with type 2 diabetes.

Indications: Ozempic is a glucagon-like peptide 1 (GLP-1) receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. It is not recommended as first-line therapy for patients inadequately controlled on diet and exercise.

Dosage and administration: Inject subcutaneously in the abdomen, thigh, or upper arm. Start at 0.25 mg once weekly. After 4 weeks, increase the dose to 0.5 mg once weekly. If after at least 4 weeks additional glycemic control is needed, increase to 1 mg once weekly. Administer once weekly at any time of day, with or without meals. If a dose is missed, administer within 5 days of missed dose.

Adverse reactions: The most common adverse reactions (≥5% of patients) are nausea, vomiting, diarrhea, abdominal pain, and constipation.

Citation:

Novo Nordisk receives FDA approval of OZEMPIC (semaglutide) injection for the treatment of adults with type 2 diabetes. [news release]. Novo Nordisk; Plainsboro, NJ; December 5, 2017. http://press.novonordisk-us.com/2017-12-5-Novo-Nordisk-Receives-FDA-Appr.... Accessed December 8, 2017.

This Week's Must Reads

Chronic Pain Among Suicide Decedents, Ann Intern Med; ePub 2018 Sep 11; Petrosky, et al

Pain and ED Use in Adults with Dementia, J Pain Symptom Manage; ePub 2018 Sep 14; Hunt, et al

Higher Optimism Predicts Lower Pain Reduction, J Pain; ePub 2018 Sep 13; Hinkle, Quiton

QOL in Patients with Chronic & Episodic Migraine, Pain Medicine; ePub 2018 Sep 14; Ceylan, et al

LIDAS as a Valid Measure for Chronic Pain, J Pain; ePub 2018 Aug 30; Wilson, et al

Must Reads in Diabetes

Statins for Prevention of CVD in the Elderly , BMJ; ePub 2018 Sep 5; Ramos, Comas-Cuff, et al

GD & Maternal Disorders of Glucose Metabolism, JAMA; 2018 Sep 11; Lowe, Scholtens, et al

Treatment Intensification Guidelines for T2D , Ann Intern Med; ePub 2018 Sep 4; Roglic, et al

Prevalence of Diabetes Among US Adults, BMJ; ePub 2018 Aug 27; Xu, Liu, et al

Aspirin for Primary CV Prevention in Diabetes, N Engl J Med; ePub 2018 Aug 26; ASCEND Study Collaborative Group